| human | Q5 |
| P2038 | ResearchGate profile ID | Mauro_Galeazzi |
| P108 | employer | University of Siena | Q1245999 |
| P734 | family name | Galeazzi | Q37441493 |
| Galeazzi | Q37441493 | ||
| Galeazzi | Q37441493 | ||
| P735 | given name | Mauro | Q1167150 |
| Mauro | Q1167150 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q42410238 | A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography |
| Q37361075 | A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. |
| Q58326219 | A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra |
| Q41989129 | A whitish-creamy synovial fluid |
| Q60622641 | AB0012 Microrna-223 in synovial tissue of rheumatoid arthritis and osteoarthritis patients |
| Q57911899 | AB0364 A Novel Approach for Rheumatoid Arthritis: Results of The Ongoing Clinical Trials with The Fully Human Immunocytokine Dekavil (F8-IL10) |
| Q43048626 | Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: further serological evidence of the disease as a subset of osteoarthritis |
| Q36146582 | Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. |
| Q39748097 | Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients |
| Q56974508 | Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis |
| Q71784683 | Allelic variations of DPB1, DQA1, DQB1 and DRB1 and rheumatoid arthritis: further genetic and statistical considerations |
| Q58326155 | Anakinra treatment in drug-resistant Behcet’s disease: a case series |
| Q58326099 | Anakinra treatment in patients with gout and type 2 diabetes |
| Q73385981 | Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE |
| Q45329549 | Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation |
| Q33331408 | Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. |
| Q43482055 | Anticardiolipin antibodies: their relationship with HLA-DR antigens in systemic lupus erythematosus |
| Q71608901 | Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis |
| Q33341941 | Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients |
| Q37414653 | Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: more than expected? |
| Q43695096 | Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis |
| Q64389006 | Association of 16/6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients. European Concerted Action on the Immunogenetics of SLE |
| Q42995397 | Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients. |
| Q46328824 | Atypical juvenile polymyositis: usefulness of magnetic resonance imaging |
| Q44899827 | Auditory involvement in Behcet's disease: relationship with demographic, clinical, and therapeutic characteristics |
| Q36999701 | Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications |
| Q37834021 | Autoinflammatory diseases and cardiovascular manifestations. |
| Q58326270 | Autoinflammatory disorders and patients with isolated serosal involvement |
| Q46934415 | Autoinflammatory syndromes. |
| Q38938321 | Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study |
| Q26781862 | Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease |
| Q38898838 | Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. |
| Q40045785 | Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review |
| Q33908217 | Biological treatments in Behçet's disease: beyond anti-TNF therapy. |
| Q37077564 | Biological treatments: new weapons in the management of monogenic autoinflammatory disorders |
| Q43049941 | Bone mineral density in patients with systemic sclerosis |
| Q38123940 | Bradykinin and its role in osteoarthritis |
| Q53093984 | Can Cannabinoids Modulate Fibrotic Progression in Systemic Sclerosis? |
| Q46121788 | Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study |
| Q54733717 | Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. |
| Q28250526 | Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments |
| Q57456608 | Categorisation of disease severity states in fibromyalgia: a first step to support decision-making in health care policy |
| Q38245566 | Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis |
| Q53562070 | Change perspective to increase diagnostic accuracy of ultrasonography in calcium pyrophosphate dehydrate deposition disease! A new approach: the axial scan of the meniscus. |
| Q53174832 | Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. |
| Q71645320 | Chromosomal abnormalities in peripheral lymphocytes from idiopathic Raynaud's phenomenon patients |
| Q38220986 | Chronic pelvic pain: comorbidity between chronic musculoskeletal pain and vulvodynia |
| Q55401064 | Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease. |
| Q37942581 | Clinical and biochemical landmarks in systemic autoinflammatory diseases |
| Q33392510 | Clinical manifestations correlated with anticardiolipin antibodies in systemic lupus erythematosus: preliminary results of a prospective study |
| Q41204508 | Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. |
| Q40297017 | Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study |
| Q33378759 | Coexistence of the antiphospholipid syndrome and abdominal aortic aneurysm |
| Q74170998 | Coexpression of CD69 and HLADR activation markers on synovial fluid T lymphocytes of patients affected by rheumatoid arthritis: a three-colour cytometric analysis |
| Q40352772 | Colchicine myopathy and neuromyopathy: two cases with different characteristics |
| Q45409529 | Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection |
| Q90900290 | Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients |
| Q43191366 | Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha |
| Q73345438 | Comparison of different methods for the detection of anti-Ro/SSA antibodies in connective tissue diseases |
| Q50995329 | Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. |
| Q91643275 | Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease |
| Q54864271 | Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. |
| Q48324635 | Could Oxidative Stress Regulate the Expression of MicroRNA-146a and MicroRNA-34a in Human Osteoarthritic Chondrocyte Cultures? |
| Q48170980 | Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study |
| Q38344512 | Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection |
| Q37765693 | Current therapeutic approaches to autoimmune chronic uveitis in children |
| Q36571776 | Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients |
| Q42119341 | Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease |
| Q36603266 | Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study |
| Q56974514 | Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50MTNFRSF1Avariant |
| Q39239316 | Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome |
| Q40337000 | Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders |
| Q28306563 | Diagnosis and classification of relapsing polychondritis |
| Q41881311 | Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome |
| Q50787766 | Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. |
| Q40905265 | Diagnostic accuracy of ultrasound, conventional radiography and synovial fluid analysis in the diagnosis of calcium pyrophosphate dihydrate crystal deposition disease |
| Q40129844 | Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. |
| Q37411976 | Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNF α Agent |
| Q90672364 | Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies |
| Q39082472 | Do MicroRNAs have a key epigenetic role in osteoarthritis and in mechanotransduction? |
| Q59033187 | Do not hallow until you are out of the wood! Ultrasonographic detection of CPP crystal deposits in menisci: facts and pitfalls |
| Q35172041 | Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders |
| Q33993099 | Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice |
| Q38406712 | Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. |
| Q45184210 | Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial |
| Q39733840 | Effect of Mud-Bath Therapy on Serum Biomarkers in Patients with Knee Osteoarthritis: Results from a Randomized Controlled Trial |
| Q38242729 | Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease |
| Q36009390 | Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort |
| Q42955864 | Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis |
| Q44916305 | Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study |
| Q40951874 | Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis |
| Q58326009 | Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series |
| Q39929401 | Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study |
| Q39181648 | Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study |
| Q39325689 | Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature |
| Q42988478 | Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection |
| Q38637585 | Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis |
| Q44929998 | Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register |
| Q45349748 | Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection |
| Q40756639 | Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study |
| Q58325873 | Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies |
| Q46558357 | Efficacy of alendronate in the treatment of the SAPHO syndrome |
| Q48669447 | Efficacy of balneotherapy on pain, function and quality of life in patients with osteoarthritis of the knee |
| Q40387413 | Efficacy of cyclosporine A treatment in relapsing febrile lobular panniculitis associated with small vessel vasculitis |
| Q71457783 | Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis |
| Q58326271 | Erratum to “Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis” [J. Autoimmun. Rev. 9(6) (2010) 436–440] |
| Q35638615 | Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects |
| Q42963024 | Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model |
| Q36929138 | Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies |
| Q48513015 | Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis |
| Q38112791 | Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis |
| Q33565525 | Expression of CD69 antigen on synovial fluid T cells in patients with rheumatoid arthritis and other chronic synovitis |
| Q57911956 | FRI0194 A phase IB clinical trial with dekavil (F8-IL10), an anti-inflammatory immunocytokine for the treatment of rheumatoid arthritis, used in combination with methotrexate |
| Q42957847 | False proteinuria in patients with alkaptonuria. |
| Q34997023 | First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). |
| Q37077793 | From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases |
| Q38709690 | Genetic aspects of the antiphospholipid syndrome: An update |
| Q67599278 | Genetics of antiendothelial cell antibodies in systemic lupus erythematosus: the role of HLA-DP alleles |
| Q38393795 | Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature |
| Q37197167 | HCV infection: pathogenesis, clinical manifestations and therapy |
| Q68996156 | HLA antigens and adult rheumatoid arthritis: a study with a monoclonal antibody |
| Q71819562 | HLA antigens and rheumatoid arthritis |
| Q41172053 | HLA antigens in Italian patients with systemic lupus erythematosus: evidence for the association of DQw2 with the autoantibody response to extractable nuclear antigens. |
| Q35556384 | HLA class II alleles and genetic predisposition to the antiphospholipid syndrome |
| Q28138464 | HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus |
| Q49084368 | HLA-B27 positive ankylosing spondylitis and polyarteritis nodosa: a case report |
| Q68086085 | HLA-DP genotyping in patients with systemic lupus erythematosus: correlations with autoantibody subsets |
| Q73737702 | HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus |
| Q69068670 | HLA-DR association in rheumatoid arthritis and the shared susceptibility epitope hypothesis |
| Q72271984 | HSP70-1 promoter region polymorphism tested in three autoimmune diseases |
| Q46361840 | Henoch-Schönlein purpura associated with pidotimod therapy |
| Q30662067 | High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register |
| Q72113333 | Hladistribution in Italian patients with fibromyalgia |
| Q53600919 | Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients. |
| Q46546592 | Human rheumatoid synoviocytes express functional P2X7 receptors |
| Q42323209 | Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway |
| Q49913433 | Hydrostatic pressure as epigenetic modulator in chondrocyte cultures: A study on miRNA-155, miRNA-181a and miRNA-223 expression levels |
| Q36888166 | Hyperhomocysteinemia, inflammation and autoimmunity |
| Q36986256 | Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases? |
| Q73108143 | III European Conference on Systemic Lupus Erythematosus. Conference summary |
| Q40204739 | IL-6 blockade in the management of non-infectious uveitis |
| Q40368852 | Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome |
| Q67902924 | Immune imbalance in the synovial fluid of rheumatoid arthritis patients: effects of intra-articular injection of thymopentin |
| Q37578118 | Immunogenetic studies on systemic lupus erythematosus |
| Q43993205 | Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide |
| Q38602457 | Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy |
| Q44650580 | Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis |
| Q47283260 | In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1β. |
| Q50142723 | Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study |
| Q47665155 | Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension |
| Q51747604 | Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. |
| Q42441850 | Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. |
| Q37641474 | Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis |
| Q46444154 | Inquiry is fatal to certainty-is the ultrasonography double contour sign specific for uric acid-induced arthritis? |
| Q39096171 | Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study |
| Q26745741 | Interleukin-1 Inhibition in Behçet's disease |
| Q35133812 | Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives |
| Q26801773 | Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders |
| Q36848308 | International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. |
| Q48867756 | International survey on the management of patients with SLE. II. The results of a questionnaire regarding neuropsychiatric manifestations |
| Q73108152 | International survey on the management of patients with SLE. III. The results of a questionnaire regarding renal involvement |
| Q71077889 | Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus |
| Q33428311 | Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature |
| Q38220758 | Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome |
| Q73063639 | Lessons from the "Euro-Lupus Cohort" |
| Q47384645 | Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry |
| Q40275882 | Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series |
| Q38841182 | Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease |
| Q54033064 | Long-term i.v. Ig treatment in systemic lupus erythematosus. |
| Q58325886 | Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis |
| Q40410081 | Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study |
| Q42274394 | Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients |
| Q44585678 | Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy |
| Q56974589 | Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors |
| Q37814184 | Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? |
| Q37999616 | MicroRNAs in autoimmune rheumatic diseases |
| Q48620779 | Modification of DNA patterns in plasma and nucleated blood cells from systemic sclerosis patients. |
| Q37299354 | Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues |
| Q33357081 | Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients |
| Q33329033 | Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus |
| Q33412915 | Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients |
| Q43519903 | Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients |
| Q42522468 | Morphological, immunocytochemical and biochemical studies in human osteoarthritic chondrocytes exposed to IL-1b and cyclical hydrostatic pressure. |
| Q26799767 | Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives |
| Q39306140 | Mud-Bath Therapy in Addition to Usual Care in Bilateral Knee Osteoarthritis: An Economic Evaluation Alongside a Randomized Controlled Trial |
| Q55216456 | Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. |
| Q38830790 | New therapeutic solutions for Behçet's syndrome |
| Q59901174 | OP0074 First Report of Circulating Micrornas in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) |
| Q45930789 | OR10-004 - Circulating micrornas in TRAPS. |
| Q46479144 | Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine |
| Q70996709 | On the heterogeneity of HLA association in juvenile rheumatoid arthritis |
| Q40170236 | PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists |
| Q55533576 | PReS-FINAL-1010: circulating micrornas in traps. |
| Q36758296 | Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey |
| Q64911379 | Phytothermotherapy in osteoarthritis: a randomized controlled clinical trial. |
| Q48367556 | Phytothermotherapy: a possible complementary therapy for fibromyalgia patients. |
| Q72213444 | Pneumocystis carinii pneumonia complicating selective CD4 T cell depletion induced by corticosteroid therapy in a patient with systemic lupus erythematosus |
| Q41741477 | Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes |
| Q58325870 | Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab |
| Q33376853 | Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study |
| Q45899885 | Prevalence of Baker's cyst in patients with knee pain: an ultrasonographic study. |
| Q39366363 | Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients |
| Q84873620 | Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? |
| Q35728708 | Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study |
| Q47784236 | Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases |
| Q56890063 | Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers |
| Q36207025 | Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease |
| Q48063595 | Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study |
| Q47691890 | Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study |
| Q47859067 | Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease |
| Q37501529 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| Q47861250 | Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. |
| Q49518769 | Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study |
| Q43050388 | Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment |
| Q71061197 | Repeat skin biopsies of nonlesional skin in patients with systemic lupus erythematosus |
| Q38703626 | Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study |
| Q52806281 | Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective. |
| Q72321397 | Rheumatic manifestations of sarcoidosis |
| Q91996662 | Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort |
| Q37268708 | Role of apoptosis in osteoporosis induced by glucocorticoids. |
| Q37822295 | Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis |
| Q45740179 | Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells |
| Q57911940 | SAT0232 A Phase IB Clinical Trial in Rheumatoid Arthritis of Dekavil (F8-IL10), A Novel Anti-Inflammatory Immunocytokine |
| Q45978191 | Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. |
| Q45367687 | Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus |
| Q43580784 | Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. |
| Q36958375 | Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection |
| Q38759644 | Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders |
| Q40630984 | Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. |
| Q58325876 | Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study |
| Q58326285 | Serosal Involvement in Adult-Onset Autoinflammatory Disorders |
| Q36178078 | Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis |
| Q56974566 | Serum amyloid-A in Behçet’s disease |
| Q40275892 | Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). |
| Q58326287 | Short- and Long-Term Effects of Spa Therapy in Knee Osteoarthritis |
| Q43482332 | Short- and long-term effects of mud-bath treatment on hand osteoarthritis: a randomized clinical trial |
| Q51747923 | Simultaneous pulmonary involvement, histologically proven, of sarcoidosis and rheumatoid arthritis. |
| Q46851590 | Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. |
| Q38262094 | Spa therapy: can be a valid option for treating knee osteoarthritis? |
| Q73473062 | Spontaneous chromosome damage (micronuclei) in systemic sclerosis and Raynaud's phenomenon |
| Q37795294 | Statins and the Joint: Multiple Targets for a Global Protection? |
| Q40489072 | Subcutaneous panniculitis-like T-cell lymphoma misdiagnosed as lupus erythematosus panniculitis |
| Q58326215 | Successful Treatment of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With Canakinumab |
| Q24647121 | Sulfasalazine-induced immune thrombocytopenia |
| Q31105857 | Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used a |
| Q40873005 | Synovial Leishmaniasis |
| Q38756600 | Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema |
| Q36399103 | Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". |
| Q40369770 | Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene |
| Q48368367 | Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis |
| Q33401164 | The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide |
| Q91156802 | The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease |
| Q38962904 | The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy |
| Q38033401 | The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature |
| Q48716230 | The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study |
| Q52768652 | The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. |
| Q38176123 | The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up |
| Q41101952 | The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant |
| Q40317701 | The laboratory approach in the diagnosis of systemic autoinflammatory diseases |
| Q38222307 | The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy |
| Q38125331 | The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review |
| Q43736074 | Thermal water of Vetriolo, Trentino, inhibits the negative effect of interleukin-1β on nitric oxide production and apoptosis in human osteoarthritic chondrocyte |
| Q49551757 | Trapped crystals in synovial fluid: neutrophil extracellular traps from bench to bedside |
| Q39307890 | Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study |
| Q37241379 | Treatment of rheumatic diseases in patients with HCV and HIV infection |
| Q87375739 | Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study |
| Q38033875 | Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives |
| Q40358488 | Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series |
| Q38240838 | Untangling the web of systemic autoinflammatory diseases |
| Q37624811 | Update on the Medical Management of Gastrointestinal Behçet's Disease. |
| Q47233623 | Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA). |
| Q21202850 | Weekly oral alendronate in mevalonate kinase deficiency |
| Q38197225 | What about strontium ranelate in osteoarthritis? Doubts and securities |
| Q50952155 | What could we learn from the sub-analysis of a single nation cohort in a worldwide study? Lessons from the results observed in the Italian cohort of the GO-MORE trial. |
| Q33357128 | Working the endless puzzle of hereditary autoinflammatory disorders |
| Q72638248 | [Absence of correlation between HLA antigens and fibromyalgia syndrome in Italian patients] |
| Q73155706 | [Chromosome aberrations, valued as frequency of spontaneous micronuclei, in subjects with suspected presclerodermic Raynaud's phenomenon] |
| Q73392706 | [Monoclonal antibody therapy] |
| Q67245385 | [Prognostic factors in Raynaud's phenomenon: usefulness of antinuclear antibodies and of periungual capillaroscopy] |
| Q70831513 | [Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis] |
| Q35014077 | miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis |
Search more.